Use of the anti-P-selectin antibody crizanlizumab for treating sickle cell nephropathy and chronic kidney disease associated with sickle cell disease

The invention relates to a method of treating chronic kidney disease due to sickle cell nephropathy in a patient in need of such treatment, comprising administering a pharmaceutically effective amount of an anti-P-selectin antibody or a binding fragment thereof to said patient and related invention...

Full description

Saved in:
Bibliographic Details
Main Authors SHARPE, Claire, INATI, Adlette, BARTOLUCCI, Pablo, DEREBAIL, Vimal, HAN, Guangyang, DEBONNETT, Laurie, ATAGA, Kenneth, LEBENSBURGER, Jeffrey, STANKOVIC, Miona, KANTER, Julie, SARAF, Santosh
Format Patent
LanguageEnglish
Published 24.03.2022
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The invention relates to a method of treating chronic kidney disease due to sickle cell nephropathy in a patient in need of such treatment, comprising administering a pharmaceutically effective amount of an anti-P-selectin antibody or a binding fragment thereof to said patient and related invention embodiments (uses, methods, pharmaceutical preparations and use in the preparation of pharmaceutical preparations).
Bibliography:Application Number: AU20200326490